2-Day versus C-reactive protein guided antibiotherapy with levofloxacin in acute COPD exacerbation: A randomized controlled trial

Mсолли Моhamed Амин 1,2, Messous Selma 2, Sekma Adel 1,2, Bel bajali Khaoula 1,2, Khalil Mohamed Hassene 1,2, Trabelsi Imen 2, Abdelghani Ahmed 3, Ben Braham Nadia 1,2, Ben Dhaya Yosra 4, Razgallah Rabie 5, Grissa Mohamed Habib 1,2, Belaiefa Kаouthar 1,2, Methame Мehdi 6, Belguith Asma 7, Bouida Wahid 1,2, Boukef Riadh 2,8, Boubaker Hamdi 1,2, Nouira Semir 1,2, on behalf of the GREAT Network

1 Emergency Department, Fattouma Bourguiba University Hospital, Monastir, Tunisia, 2 Research Laboratory LR12SP18, Monastir University, Monastir, Tunisia, 3 Pneumology Department, Farhat Hached University Hospital, Sousse, Tunisia, 4 Medis Laboratories, Tunis, Tunisia, 5 DACIMA Consulting, Tunis, Tunisia, 6 Emergency Department, Farhat Hached University Hospital, Sousse, Tunisia, 7 Department of Preventive Medicine, Fattouma Bourguiba University Hospital, Monastir, Tunisia, 8 Emergency Department, Sahliou University Hospital, Sousse, Tunisia

☯ These authors contributed equally to this work.
¶ Membership the GREAT Network is provided in the Acknowledgments.
* belhajakhaoula@yahoo.fr

Abstract

Introduction
Duration of antibiotic treatment in acute exacerbation of COPD (AECOPD) is most commonly based on expert opinion. Biomarker guided strategy is increasingly recommended to limit unnecessary antibiotic use. We performed a randomized controlled study to evaluate the efficacy of 2-day versus C-reactive protein (CRP)-guided treatment with levofloxacin in patients with AECOPD.

Methods
Patients with AECOPD were randomized to receive oral levofloxacin daily for 7 days unless the serum CRP level decreased by at least 50% from the baseline value or levofloxacin for two days; thereafter, oral placebo tablet was prescribed according to the CRP. The primary outcome measure was cure rate, and secondary outcome included need for additional antibiotics, intensive care unit (ICU) admission, exacerbation rates and exacerbation free interval (EFI) within one-year follow-up.

Results
In intention to treat (ITT) analysis, cure rate was 76.1% (n = 118) and 79.3% (n = 123) respectively in 2-day and CRP-guided groups. In per protocol (PP) analysis, cure rate was 73% (n = 92) and 70.4% (n = 88) respectively in 2-day and CRP-guided groups. The
difference between the two groups was not significant. The need for additional antibiotics and ICU admission rates were not significantly different between the two groups. One-year exacerbation rate was 27% (n = 42) in 2-day group versus 30.3% (n = 47) in CRP-guided group (p = 0.53); the EFI was 125 days (interquartile range, 100–151) versus 100 days (interquartile range, 78–123) in 2-day and CRP-guided groups respectively (p = 0.45). No difference in adverse effects was detected.

Conclusion
Levofloxacin once daily for 2 days had similar efficacy compared to CRP-guided in AECOPD. This short course treatment decreased antibiotic consumption which would improve patient compliance and reduce adverse effects.

Introduction
Chronic obstructive pulmonary disease (COPD) is a common disease worldwide and a leading cause of death and disability globally [1–3]. Given that bacteria are implicated in a substantial proportion of acute exacerbation of COPD (AECOPD), antibiotics are frequently used. However, this current practice may lead to antibiotic overuse further increasing drug resistance and side effects [4–10]. Implementing specific rules that reduce unnecessary antibiotherapy prescription and duration is highly beneficial [11,12]. Available studies showed that antibiotic treatment could be shortened and this could be achieved with or without the aid of biomarkers. Guidelines stated that antibiotic treatment should be maintained at an average of 7 to 10 days while some studies showed the non-clinical inferiority of courses as short as 3 days in many specific diseases like respiratory infections and AECOPD [13–15]. C-reactive protein (CRP) is an acute phase protein that rises rapidly in infections and is considered a useful biomarker to guide antibiotherapy in AECOPD [16–18]; however, there was no trials comparing clinical effectiveness and cost-effectiveness of CRP-guided strategy and a fixed short course of antibiotic in AECOPD patients. Hence, we conducted this study to compare the efficacy of a 2-day course of levofloxacin with CRP-guided antibiotic prescription in AECOPD.

Materials and methods
Study design
We conducted a prospective, randomized, double-blinded controlled study from May 2017 to January 2019 including patients with AECOPD admitted to the emergency department (ED). Fattouma Bourguiba university hospital ethic committee, Sahloul university hospital ethic committee and Farhat Hached university hospital ethic committee approved the study before implementation, and all included patients provided written informed consent. Also, the study protocol was prepared in accordance with the revised Helsinki Declaration for Biomedical Research Involving Human Subjects and Guidelines for Good Clinical Practice and was registered at www.clinicaltrials.gov: NCT02067780.

Settings and participants
This study included adult patients admitted to three EDs (Fattouma Bourguiba University Hospital Monastir, Sahloul University Hospital Sousse, and Farhat Hached University...
Patients were eligible for inclusion in the cohort if they were 45 years or older and had a clinical diagnosis of COPD defined according to the Global Initiative of Chronic Obstructive Lung Disease (GOLD). AECOPD was defined as a change in patients’ baseline dyspnea, cough, or sputum beyond day-to-day variability, sufficient to warrant a change in management other than optimization of bronchodilator therapy. Patients were excluded if they presented with one of the following conditions: clinical evidence of hemodynamic compromise with the need for vasoactive drugs, immediate need for mechanical ventilation, Glasgow coma scale < 12, pneumonia, previous adverse reactions to the study drug, antibiotic treatment in the previous days, pregnancy or lactation, severe renal (creatinine clearance 40 mL/min) or hepatic impairment, or lung disease other than COPD that could affect the clinical evaluation of the treatments. Patients with active alcohol or drug abuse were also excluded.

Randomization and intervention

For all included patients, demographic, clinical, and biological data were collected at baseline. These included the patients’ comorbidities, number of exacerbations in the past year, physical examination findings, blood gas analysis, and standard laboratory test results. Expectorated sputum samples were collected for pathogen culture, and all data were recorded in standardized electronic case report forms. Noninvasive ventilation (NIV) was performed for patients with an arterial carbon dioxide partial pressure >45 mmHg and pH <7.35, using supplemental oxygen to obtain a pulse oxygen saturation >90%. Patients were randomly assigned (1:1) to one of two treatment arms: (1) the intervention (CRP-guided) group: 500 mg (one tablet) of oral levofloxacin daily for 7 days unless the serum CRP level decreased by at least 50% from the baseline value. The serum CRP levels were measured at the ED admission on days 2, 4, and 6, and made available to the attending physicians. (2) The standard care (control) group: 500 mg of levofloxacin daily for the first two days; thereafter, the oral placebo tablet was prescribed according to the CRP values as in the CRP-guided group to maintain the blindness of the study. The randomization sequence was generated using a sealed envelope sequence generator stratified according to the investigator site. Online inclusion of patients according to the concealed sequence was performed with an independent, centralized web-based system (DACIMA Tunisia; https://www.dacimasoftware.com). Additionally, to ensure blinding, active drugs, as well as the placebo tablets, were encapsulated for identical appearance and placed in sealed envelopes. All patients who received at least one dose of the study medication comprised the intent-to-treat (ITT) population and were treated in the ED during the first 48 hours (h). Also, all patients received intravenous methylprednisolone (0.3 mg/kg every 6h), nebulized bronchodilator, and fluid therapy, while other medications were prescribed at the attending physician’s discretion. After 48-h ED stay, patients were discharged if their condition improved; otherwise, they were hospitalized in the ward or ICU if they required intubation or needed NIV. All the patients were monitored over seven days, adverse effects including photosensitivity, nausea, diarrhea, headache, tendinitis, tendon rupture, hyper-hypoglycemia, seizures, prolonged QT interval, and peripheral neuropathy, were reported and rated by the investigator as possibly, probably, or related to the study treatment. Long-term follow-up was made by phone contact on the 15th day of every month for 12 months after the study treatment. If the patient was not reachable, the next of kin and/or the patient’s general practitioner were contacted. Physicians who collected outcome data were not aware of the treatment allocation. The vital status, time to next acute exacerbation, and exacerbation-free interval (EFI) were recorded with each phone communication.
Outcome analysis

Outcome analysis were performed on the intent-to-treat and per-protocol (PP) populations. Clinical cure rate was considered as the primary outcome. It was defined as resolution of acute signs and symptoms of AECOPD to baseline level (non-exacerbated state), together with resolution of fever if present at inclusion study entry and no reason for treatment failure. Secondary outcome included EFI, ICU admission rate, and need for additional antibiotics. The decision to initiate new antibiotics was left to the discretion of the treating physician. One-year exacerbation and death rates were considered as secondary outcome. The antibiotic sparing effect was also assessed; it was defined as the duration of levofloxacin treatment possibly saved with 2-day regimen compared to CRP-guided strategy.

Statistical analysis. The primary objective was to demonstrate that levofloxacin treatment for 2 days was non-inferior to CRP-guided treatment. Analysis at follow-up for the primary outcome was based on the ITT population and per-protocol (PP) population. Data from previous studies, used to estimate the frequency of the primary outcome of the present study, suggested that exacerbations within 1 year occurred in approximately 50% of the patients. To define the non-inferiority of the 2-day course compared to the CRP-guided treatment, we selected a 15% difference in the percentage of cure rate as a clinically tolerable upper limit. We hypothesized that cure rates for the two treatment plans would be equal (at 80%) and considered a difference of ≤15% to be irrelevant. Then, setting β = 0.20 and α = 0.05 (one-tail), the estimated sample size was 140 patients per arm. Taking into account an estimated 10% dropout rate of patients at 6-month follow-up, we increased the sample size to 155 patients per arm. Qualitative data were described with frequencies and percentages; quantitative data were described with the mean ± standard error or with the median, interquartile interval, and range. Baseline characteristics of the patients were compared with the unpaired t-test or the Wilcoxon rank sum test for continuous variables, depending on their distributions. Percentage differences were compared using the Fisher’s exact test (or χ² test, when appropriate). In case of skewed distributions, continuous variables were logarithmically transformed for further analysis. Comparisons of the incidence rates of AEs between the two study groups were performed descriptively. No interim analysis was planned or performed for this study. All statistical tests were two-sided and performed at a 0.05 significance level using the SPSS software, version 20.0.

Results

A total of 500 patients were screened, and 310 patients were randomized (ITT population) to receive a 2-day course of levofloxacin (n = 155), or CRP-guided protocol (n = 155). The PP population comprised 251 patients at the end of follow-up with 126 and 125 patients, respectively, for the 2-day and CRP-guided groups (Fig 1). Main reason for withdrawing patients from the ITT analysis was incomplete (end-of therapy) evaluation (29 patients in 2-day group and 30 patients in CRP-guided group). A description of the baseline characteristics of the patients is given in Table 1. The two treatment groups had similar baseline demographics and clinical findings (Table 1), as well as similar severity criteria of the episode as assessed by the number of exacerbations during the previous year and according to the Anthonisen classification. The median duration of treatment in the CRP-guided group was 3.6 days (interquartile intervals: 3.0–3.9). The two treatment groups were similar in the number of pathogens isolated at pre-therapy (52 versus 47, respectively, in the 2-day and CRP-guided groups). Haemophilus influenzae and chlamyphilia pneumoniae which were isolated respectively from 18 and 15 patients, were the most common pathogens found (Table 2). CRP decreased significantly in
the two groups over time compared to baseline values; this decrease was comparable between groups (Fig 2).

Clinical outcomes for the ITT and PP populations showed that a 2-day regimen of levofloxacin was non-inferior to a CRP-guided strategy (Table 3). In ITT population, cure rate was similar in the 2 groups [76.1% and 79.3% in the 2-day group and CRP-guided group respectively; HR 1.46; 95% CI, 0.83 to 2.59; p = 0.49]. In PP population, cure rate was 73% and 70.4% in the 2-day group and 7-day group respectively (HR 1.00; 95% CI, 0.66 to 1.50; p = 0.65).

**Secondary outcome**

Data regarding secondary outcome in ITT population are shown in Table 3. Rate of additional antibiotic prescriptions was similar in the two groups [11.6% and 9% in the 2-day group and...
Table 1. Patients’ demographic and clinical characteristics at admission*.

|                                      | 2-day group n = 155 | CRP-guided group n = 155 | p-value |
|--------------------------------------|---------------------|--------------------------|---------|
| Age years, mean (SD)                 | 68.5±10.1           | 66.7±10.5                | 0.12    |
| Sex ratio M/F                        | 131/21              | 135/20                   | 0.81    |
| Smoking (pack-years), mean (SD)      | 53.4±13.2           | 67.2±15.6                | 0.15    |
| Peak Expiratory Flow (L/min), mean (SD) | 62.6±15.9          | 64.4±18.6                | 0.12    |
| Body mass index (kg.m\(^2\)), mean (SD) | 26.8±7.5            | 26.4±4.5                 | 0.62    |
| Exacerbations within the past year, mean (SD) | 2.1±1.8             | 2.4±1.9                  | 0.11    |
| Past medical history n (%)           |                     |                          |         |
| Hypertension                         | 45(29)              | 48(30.9)                 | 0.76    |
| Heart failure                        | 8(5.16)             | 1(0.64)                  | 0.01    |
| Diabetes                             | 21(13.5)            | 27(17.4)                 | 0.39    |
| Anthonisen classification n (%)      |                     |                          |         |
| Type 1                               | 34(21.9)            | 40(25.8)                 | 0.42    |
| Type 2                               | 121(78.1)           | 115(74.2)                |         |
| Blood pressure                       |                     |                          |         |
| Systolic mmHg, mean (SD)             | 138.2±29.1          | 136.2±25.2               | 0.54    |
| Diastolic mmHg, mean (SD)            | 76.7±24.4           | 71.1±21.3                | 0.03    |
| Temperature (°C), mean (SD)          | 37.1±0.8            | 37.0±0.5                 | 0.47    |
| Pulse rate (b/min), mean (SD)        | 105.3±23.1          | 106.7±25.7               | 0.64    |
| Respiratory rate (c/min), mean (SD)  | 26.4±5.4            | 26.3±8.6                 | 0.9     |
| Blood gas                            |                     |                          |         |
| pH, median (IQR)                     | 7.33(7.31–7.36)     | 7.32(7.30–7.36)          | 0.11    |
| PaCO\(_2\) (mmHg), median (IQR)      | 41.9(39.9–45.5)     | 44.1(40.9–47.3)          | 0.5     |
| White blood cells (x 10\(^7\)/mm\(^3\)) | 13.35±11.12         | 12.83±4.97               | 0.61    |
| C-reactive protein (mg/L), median (IQR) | 60.61(45.12–76.11)  | 51.88(40.63–77.11)       | 0.37    |
| Median duration of therapy, median (IQR) | 2                   | 3.6 (3–3.9)              | 0.19    |

* Intention-to-treat population.
Abbreviations: M/F: Male/female; IQR: Interquartile range.

https://doi.org/10.1371/journal.pone.0251716.t001

Table 2. Bacteriologic results.

|                              | 2-day group | CRP-guided group |
|------------------------------|-------------|------------------|
| Branhamella catarrhalis      | 5           | 4                |
| Escherichia coli             | 1           | 3                |
| Haemophilus influenzae       | 10          | 8                |
| Haemophilus parainfluenzae   | 1           | 4                |
| Klebsiella pneumoniae        | 3           | 0                |
| Proteus mirabilis            | 1           | 0                |
| Pseudomonas aeruginosa       | 7           | 4                |
| Branhamella catarrhalis      | 6           | 4                |
| Providencia                  | 0           | 1                |
| Acinetobacter spp            | 1           | 2                |
| Mycoplasma pneumoniae        | 1           | 3                |
| Acinetobacter baumannii      | 4           | 1                |
| Chlamydophila pneumoniae     | 8           | 7                |
| Coxiella burnetii            | 4           | 6                |
| Total                        | 52          | 47               |

https://doi.org/10.1371/journal.pone.0251716.t002
CRP-guided group respectively; \( p = 0.45 \). ICU admission rate was 6.4% in the 2-day group and 7% in the CRP-guided group \( p = 0.82 \). One-year exacerbation rate was not significantly different between the 2 groups (27% versus 30.3% in the 2-day group and CRP-guided group

![C-reactive protein values at baseline and day 2, 4 and 6. CRP: C-reactive protein.](https://doi.org/10.1371/journal.pone.0251716.g002)

Table 3. Patients’ outcome.

|                      | 2-day group n = 155 | CRP-guided group n = 155 | P value | HR (95% CI) |
|----------------------|---------------------|--------------------------|---------|-------------|
| **Primary Outcome**  |                     |                          |         |             |
| Cure rate, n (%)     |                     |                          |         |             |
| ITT                  | 118(76.1)           | 123(79.3)                | 0.49    | 1.46(0.83–2.59) |
| PP                   | 92(73.0)            | 88(70.4)                 | 0.65    | 1.00(0.66–1.50) |
| **Secondary outcomes** |                    |                          |         |             |
| Need for Additional Antibiotic Therapy, n (%) |                     |                          |         |             |
| ITT                  | 18 (11.6)           | 14(9)                    | 0.45    | 1.04(0.54–2.00) |
| PP                   | 12(9.5)             | 10(8)                    | 0.67    | 1.42(0.74–2.72) |
| ICU Admissions, n (%) |                     |                          |         |             |
| ITT                  | 10(6.4)             | 11(7)                    | 0.82    | 0.79(0.35–1.77) |
| PP                   | 6(4.7)              | 8(6.4)                   | 0.57    | 1.10(0.49–2.45) |
| Exacerbation free interval days, median (IQR) |                     |                          |         |             |
| ITT                  | 125(100–151)        | 100(78–123)              | 0.45    | 1.001(0.99–1.004) |
| PP                   | 125(100–151)        | 99(76–121)               | 0.42    | 1.001(0.99–1.004) |
| One-year mortality, n (%) |                    |                          |         |             |
| ITT                  | 12(7.7)             | 7(4.5)                   | 0.23    | 3.15(1.82–5.45) |
| PP                   | 12(9.5)             | 7(5.6)                   | 0.24    | 3.15(1.82–5.45) |
| One-year exacerbation rate, n (%) |                    |                          |         |             |
| ITT                  | 42(27)              | 47(30.3)                 | 0.53    | 49.45(15.67–156.54) |
| PP                   | 42(33.3)            | 47(37.6)                 | 0.48    | 49.45(15.67–156.54) |

Abbreviations: ITT intention-to-treat population; PP per-protocol population (2-day group n = 126; CRP-guided group n = 125); ICU intensive care unit.
respectively; \( p = 0.53 \). EFI was similar in the two treatment groups [125 days (interquartile range 100–151) versus 100 days (interquartile range 79–123) in the 2-day and CRP-guided groups respectively; \( p = 0.45 \)]. The net antibiotic sparing effect with the 2 days levofloxacin fixed dose ranged from 1 to 2 days (median = 1.6 days).

**Safety**

AEs were reported in one patient in the 2-day group. The incidence of AEs was very low in this study, with only one patient in the 2-day group; however, this was mild and did not require discontinuation of the treatment study.

**Discussion**

Our results showed that in patients admitted with AECOPD, a 2-day course of levofloxacin was not clinically inferior to CRP-guided treatment in terms of cure rate, need for additional antibiotics, ICU admission, exacerbation free interval, and one-year exacerbation rate.

Inappropriate antibiotic use is frequent and represents the main risk factor for bacterial resistance. In this regard, reducing unnecessary prescription of antibacterial agents play a crucial role to maintain antibiotic effectiveness. Shortening antibiotic therapy duration could be one method to limit this increasing challenge, provided the clinical efficacy is not impaired. Previous studies have been performed to evaluate this possibility in AECOPD [19]. Stolbrink et al. conducted a meta-analysis, including 10 randomized controlled trials in which short and standard courses of antibiotics belonging to the same classes were compared [20]. Three of the studies involving fluoroquinolones were in favor of short-course treatment. Overall, the typical administration periods range from 5 to 14 days, but the evidence regarding the ideal index duration for antibiotics is limited. Several well-designed trials found that biomarker-based guidance in the treatment of AECOPD reduced the use of antibiotics with no apparent harm to patients [12]. Increasing data support the use of CRP and procalcitonin (PCT) treatment algorithms as an evidence-based approach to more individualized and judicious use of antibiotics in AECOPD [16,21]. One study has demonstrated that AECOPD patients admitted to the hospital with CRP \( \geq 50 \) mg/L possibly benefitted more from antibiotics than patients with low CRP values [22]. Similar results were found in another study using a cutoff point of 40 mg/L [23]. In a recent multicenter, open-label, randomized, controlled trial conducted in the UK and Wales, Butler et al. showed that for patients with CRP <20 mg/L, antibiotics were unlikely to be beneficial and, in contrast, for those with a CRP >40 mg/L, antibiotics were likely to be beneficial [17]. Interestingly, almost all of our patients had a CRP level \( >40 \) mg/L and using CRP-guided strategy was associated with a reduction of antibiotic therapy duration to 3.6 days compared to the 7 to 10 day-regimen currently recommended. However, this duration is still higher than 2-day course which is found to be as effective. This means that CRP-guided strategy is useful to reduce antibiotic prescription but not sufficiently sensitive to titrate treatment duration. We estimate that 2 days could be the lowest effective antibiotic course in AECOPD and could be recommended to decrease the emergence of antimicrobial resistance and minimize costs. The effectiveness of such a short course of antibiotics means that the early infection period is the most sensitive to antibiotic effects, allowing a maximum decrease in the bacterial growth and for the immune system to gain time to acquire an enhanced ability to fight the microorganism [24]. Our findings also suggest that sterility of the infection site is not necessary for clinical healing and that the dogma that stopping antibiotic treatment early encourages resistance to antibiotics is not evidence-based [25]. Bacterial resistance due to post-antibiotic effect (PAE) is another potential factor that sustains the effectiveness of short antibiotic courses [26]. It refers to the suppression of bacterial growth, which persists after brief exposure of
organisms to antimicrobials. Similar to aminoglycosides, fluoroquinolones have concentration-dependent bactericidal activity and prolonged PAE [27]. However, the exact duration of the PAE, which is also species-dependent, is unknown.

The main strength of our study is that it was double-blinded, which is not common in trials using a biomarker algorithm. Hospital staff and investigators were blinded to the randomization results, allowing for a low risk of performance bias. Also, this was a multicentric study, conducted over three years and covering all the four seasons, with minimal loss to follow up.

Our findings must be interpreted in the context of several potential limitations. First, since we only used levofloxacin in this study, it is uncertain if similar results would be obtained in response to other antibiotics. Therefore, extrapolating our results to other antibiotic classes is presumptive. Furthermore, patients with hemodynamic or respiratory instability requiring intensive care unit and mechanical ventilation were excluded. Therefore, our results cannot be extrapolated to unstable COPD exacerbations. Additionally, it was suggested that PCT is a specific biomarker for bacterial infections, more than CRP. However, PCT-guided strategies are relatively expensive, whereas CRP is cheap and widely available. Hence, cost-effectiveness comparisons are significant when comparing PCT and CRP-guided antibiotic strategies. Further, it could be argued that the patients conditions’ included in this study were not severe enough to require antibiotic therapy; this explains the lack of difference observed between two strategies in this study. Notably, however, all our patients were below the type 1 or 2 of the Anthonisen classification. Moreover, most patients had high CRP levels at their inclusion. Lastly, due to the relatively limited data regarding the optimal cutoff values that should be used in CRP-guided algorithms, it is not possible to anticipate whether different cutoffs or algorithms will be associated with different results.

**Conclusion**

Our study showed that a 2-day course of levofloxacin was not inferior to a CRP-guided strategy, but exposes to a less antibiotic consumption.

**Supporting information**

S1 File. Consort checklist.  
(DOC)

S2 File.  
(RAR)

**Acknowledgments**

The authors acknowledge all of our Research Laboratory LR12SP18 University of Monastir members who contributed greatly to this study.

GREAT network membership list:

- Professor Christian Muller  
  M.D., Department of Cardiology Medicine University of Basel.
- Professor Alexandre Mebazaa  
  M.D., Ph.D., Department of Anesthesiology and Critical Care Medicine University of Paris Diderot
- Prof. Salvatore Di Somma  
  M.D., Ph.D. Emergency Medicine Department of Medical-Surgery Sciences and Translational Medicine, University La Sapienza.
**Author Contributions**

Conceptualization: Msolli Mohamed Amine, Bel haj ali Khaoula, Ben Dhaya Yosra, Boubaker Hamdi.

Data curation: Messous Selma.

Formal analysis: Sekma Adel, Bel haj ali Khaoula, Beltaief Kaouthar.

Methodology: Belguith Asma.

Project administration: Beltaief Kaouthar.

Resources: Khalil Mohamed Hassene.

Software: Trabelsi Imen, Razgallah Rabie.

Supervision: Msolli Mohamed Amine, Grissa Mohamed Habib, Bouida Wahid.

Validation: Abdelghani Ahmed, Boubaker Hamdi.

Visualization: Ben Brahim Nadia, Methamem Mehdi, Boukef Riadh.

Writing – original draft: Nouira Semir.

Writing – review & editing: Bel haj ali Khaoula.

**References**

1. Donaldson GC, Wedzicha JA. COPD exacerbations 1: Epidemiology. Thorax. févr 2006; 61(2):164–8. https://doi.org/10.1136/thx.2005.041806 PMID: 16443707

2. Hurst JR. Exacerbation Phenotyping in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 15 sept 2011; 184(6):625–6. https://doi.org/10.1164/rccm.201106-1136ED PMID: 21920921

3. Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. Am J Respir Crit Care Med. 01 2017; 195(5):557–82. https://doi.org/10.1164/rccm.201701-0218PP PMID: 28128970

4. López-Campos JL, Hartl S, Pozo-Rodriguez F, Roberts CM. Antibiotic Prescription for COPD Exacerbations Admitted to Hospital: European COPD Audit. PLoS One. 2015 Apr 23; 10(4):e0124374. https://doi.org/10.1371/journal.pone.0124374 PMID: 25905726

5. Jacobs DM, Pandit U, Sethi S. Acute exacerbations in chronic obstructive pulmonary disease: should we use antibiotics and if so, which ones? Curr Opin Infect Dis. 2019; 32(2):143–51. https://doi.org/10.1097/QCO.0000000000000533 PMID: 30672788

6. Miravitlles M, Anzueto A. Antibiotics for Acute and Chronic Respiratory Infection in Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 7 aouût 2013; 188(9):1052–7. https://doi.org/10.1164/rccm.201302-0289PP PMID: 23924286

7. White AJ, Gompertz S, Stockley RA. Chronic obstructive pulmonary disease. 6: The aetiology of exacerbations of chronic obstructive pulmonary disease. Thorax. janv 2003; 58(1):73–80. https://doi.org/10.1136/thorax.58.1.73 PMID: 12511727

8. Roede BM, Bresser P, Bindels PJF, Kok A, Prins M, ter Riet G, et al. Antibiotic treatment is associated with reduced risk of a subsequent exacerbation in obstructive lung disease: an historical population based cohort study. Thorax. nov 2008; 63(11):968–73. https://doi.org/10.1136/thx.2008.095349 PMID: 18682520

9. Desai H, Richter S, Doern G, Heilmann K, Dohn C, Johnson A, et al. Antibiotic resistance in sputum isolates of Streptococcus pneumoniae in chronic obstructive pulmonary disease is related to antibiotic exposure. COPD. oct 2010; 7(5):337–44. https://doi.org/10.3109/15412555.2010.510162 PMID: 20854048

10. Pérez-Trailero E, Marimón JM, González A, Ercibengoa M, Larruskain J. In vivo development of high-level fluoroquinolone resistance in Streptococcus pneumoniae in chronic obstructive pulmonary disease. Clin Infect Dis Off Publ Infect Dis Soc Am. 15 août 2005; 41(4):560–4. https://doi.org/10.1086/432062 PMID: 16028189

11. Seok H, Jeon JH, Park DW. Antimicrobial Therapy and Antimicrobial Stewardship in Sepsis. Infect Chemother. mars 2020; 52(1):19–30. https://doi.org/10.3947/ic.2020.52.1.19 PMID: 32239809
12. Hurst JR, Donaldson GC, Perera WR, Wilkinson TMA, Bilello JA, Hagan GW, et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 15 Oct 2006; 174(8):867–74. https://doi.org/10.1164/rccm.200604-506OC PMID: 16799074

13. Hanretty AM, Gallagher JC. Shortened Courses of Antibiotics for Bacterial Infections: A Systematic Review of Randomized Controlled Trials. Pharmacotherapy. 2018; 38(6):674–87. https://doi.org/10.1002/phar.2118 PMID: 29679383

14. Roede BM, Bresser P, El Moussaoui R, van den Berg BTJ, Hooghiemstra PM, et al. Three vs. 10 days of amoxicillin-clavulanic acid for type 1 acute exacerbations of chronic obstructive pulmonary disease: a randomised, double-blind study. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. Mar 2007; 13(3):284–90. https://doi.org/10.1111/j.1469-0691.2006.01638.x PMID: 17391383

15. Anzueto A, Miravitlles M. Short-course fluoroquinolone therapy in exacerbations of chronic bronchitis and COPD. Respir Med. Oct 2010; 104(10):1396–403. https://doi.org/10.1016/j.rmed.2010.05.018 PMID: 20580215

16. Daniels JMA, Schoorl M, Snijders D, Knol DL, Lutter R, Jansen HM, et al. Procalcitonin vs C-reactive protein as predictive markers of response to antibiotic therapy in acute exacerbations of COPD. Chest. Nov 2010; 138(5):1108–15. https://doi.org/10.1378/chest.09-2927 PMID: 20576731

17. Butler CC, Gillespie D, White P, Bates J, Lowe R, Thomas-Jones E, et al. C-Reactive Protein Testing to Guide Antibiotic Prescribing for COPD Exacerbations. N Engl J Med. 11 2019; 381(2):111–20. https://doi.org/10.1056/NEJMo1803185 PMID: 32191514

18. Francis NA, Gillespie D, White P, Bates J, Lowe R, Sewell B, et al. C-reactive protein point-of-care testing for safely reducing antibiotics for acute exacerbations of chronic obstructive pulmonary disease: the PACE RCT. Health Technol Assess Winch Engl. Mar 2020; 24(15):1–108. https://doi.org/10.3310/hta24150 PMID: 32202490

19. Rice LB. The Maxwell Finland Lecture: For the Duration—Rational Antibiotic Administration in an Era of Antimicrobial Resistance and Clostridium difficile. Clin Infect Dis. 15 Feb 2008; 46(4):491–6. https://doi.org/10.1086/526535 PMID: 18194098

20. Stolbrink M, Amiry J, Blakey JD. Does antibiotic treatment duration affect the outcomes of exacerbations of asthma and COPD? A systematic review. Chron Respir Dis. Aug 2018; 15(3):225–40. https://doi.org/10.1177/1479972317745734 PMID: 29232988

21. Li Z, Yuan X, Yu L, Wang B, Gao F, Ma J. Procalcitonin-guided antibiotic therapy in acute exacerbation of chronic obstructive pulmonary disease: An updated meta-analysis. Medicine (Baltimore). 2019 Aug; 98(32):e16775. https://doi.org/10.1097/MD.0000000000016775 PMID: 31393400

22. Daniels JMA, Snijders D, de Graaff CS, Vlasvolder F, Jansen HM, Boersma WG. Antibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 15 Jan 2010; 181(2):150–7. https://doi.org/10.1164/rccm.200906-0837OC PMID: 19875685

23. Llor C, Moragas A, Hernández S, Bayona C, Miravitlles M. Efficacy of antibiotic therapy for acute exacerbations of mild to moderate chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 15 Oct 2012; 186(7):716–23. https://doi.org/10.1164/rccm.201206-0996OC PMID: 22923662

24. Azar B. Profile of Bruce Levin. Proc Natl Acad Sci. 10 Jun 2014; 111(23):8316–8. https://doi.org/10.1073/pnas.1408161111 PMID: 24912161

25. Waid-Dickler N, Spellberg B. Short-course Antibiotic Therapy-Replacing Constantine Units With « Shorter Is Better ». Clin Infect Dis Off Publ Infect Dis Soc Am. 15 2019; 69(9):1476–9.

26. MacKenzie FM, Gould IM. The post-antibiotic effect. J Antimicrob Chemother. Oct 1993; 32(4):519–37. https://doi.org/10.1093/jac/32.4.519 PMID: 8288494

27. Turnidge J. Pharmacokinetics and Pharmacodynamics of Fluoroquinolones. Drugs. 1 Oct 1999; 58 (2):29–36. https://doi.org/10.2165/00003495-19995802-00006 PMID: 10553702